Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Qiagen N.V. (0H1Z)

  Print      Mail a friend       Annual reports

Monday 25 May, 2009

Qiagen N.V.

QIAGEN Launches Novel Product Enabling Non-Inva...

 QIAamp kit sets new standard for the extraction of free circulating
                               DNA and
                    RNA fragments in human blood

Venlo, The Netherlands, May 25,  2009 --- QIAGEN today announced  the
launch  of  a  novel  product  for  extraction  of  free  circulating
fragments of tumor- and fetal-derived nucleic acids as well as  viral
nucleic acids in human blood.  Scientists consider these DNA and  RNA
fragments to  have  great  potential for  the  highly  sensitive  and
non-invasive  diagnosis  of  a  wide  range  of  diseases,  including
congenital disorders, malignancies such as colon and lung cancer, and
infections. The new QIAamp Circulating  Nucleic Acid Kit is  expected
to significantly facilitate the corresponding biomarker research  and
the introduction  of novel  molecular tests  in prenatal  diagnostics
which can replace risky, invasive procedures such as amniocentesis.

Free circulating DNA and RNA fragments are found in body fluids  such
as plasma, serum and urine. Scientific research has demonstrated that
plasma, in  particular,  carries  a variety  of  nucleic  acids  from
viruses  and  different  tissues   throughout  the  body,   including
developing fetuses and tumors. In  cancer research, it has also  been
shown that the concentration of tumor DNA fragments is related to the
extent of the  disease. The analysis  of such DNA  and RNA  fragments
thus not only enables new,  virtually non-invasive approaches to  the
early and highly sensitive  detection of different malignancies  such
as colon or lung cancer, but can also help to monitor the progress of
the disease and to assess  patient outcomes. Likewise, fetal DNA  and
RNA  fragments  circulating  in  maternal  blood  can  be  used   for
the non-invasive  molecular  detection  of  congenital  disorders  in
prenatal diagnostics,  an  area  where QIAGEN  also  cooperates  with
Sequenom, Inc. which is a leader in this field.

QIAGEN's new QIAamp Circulating Nucleic  Acid Kit for the first  time
enables the isolation and purification of all types and all sizes  of
nucleic acids from large-scale plasma and serum samples - and thereby
enables unprecedented  yields  of  the  isolated  molecules  and  the
highest sensitivity  of downstream  applications. This  significantly
facilitates  the  molecular  detection  of  viral  infections,  where
extraction of even the scarcest traces  of genetic material is a  key
requirement for reliable results.  Moving forward, the company  plans
to extend the use of the  product to urine samples and the  isolation
of free circulating miRNA molecules from plasma and serum, which  can
serve as highly specific biomarkers for cancer.

"Our new product brings major improvements to biomarker research  for
cancer  and  the   development  of   novel,  virtually   non-invasive
diagnostics based  upon nucleic  acid fragments  circulating in  body
fluids", said Uwe Oelmueller,  Senior Director R&D Diagnostic  Sample
Preparation and Stabilization at QIAGEN. "The clinical value of  this
method is  well documented,  but  its widespread  implementation  and
progress in further research have been hampered by the cumbersome and
demanding methodology for handling such molecules. The new QIAamp kit
removes  this  bottleneck  and  will  bring  significant  value   for
researchers and clinicians."

The novel  kit is  currently  available for  research use  only.  The
company  plans  to  validate  the  product  for  in-vitro  diagnostic
applications in the United States and Europe.

QIAGEN   N.V.,    a    Netherlands   holding    company,    is    the
leading global provider of  sample  and  assay  technologies.  Sample
technologies are used to  isolate and process  DNA, RNA and  proteins
from biological samples such  as blood or tissue. Assay  technologies
are used  to  make such  isolated  biomolecules visible.  QIAGEN  has
developed and markets more than 500 sample and assay products as well
as automated solutions for such consumables. The company provides its
products to molecular diagnostics laboratories, academic researchers,
pharmaceutical   and    biotechnology    companies,    and    applied
testing customers for  purposes such  as forensics,  animal  or  food
testing   and   pharmaceutical   process   control. QIAGEN's    assay
technologies  include  one  of  the  broadest  panels  of   molecular
diagnostic tests available worldwide. This panel includes the  digene
HPV Test, which  is regarded as  the "gold standard"  in testing  for
high-risk types of human papillomavirus  (HPV), the primary cause  of
cervical cancer. QIAGEN  employs more  than 3,100 people  in over  30
locations worldwide. Further information about QIAGEN can be found at

Statements contained in  this release that  are not historical  facts
are  forward-looking  statements,  including  statements  about   our
products, markets, strategy  and operating  results. Such  statements
are  based   on  current   expectations   that  involve   risks   and
uncertainties including, but not  limited to, those associated  with:
management of growth and international operations (including currency
fluctuations and logistics),  variability of  our operating  results,
commercial development  of our  markets (including  applied  testing,
clinical  and  academic  research,  proteomics,  women's   health/HPV
testing and molecular diagnostics), our relationships with customers,
suppliers and strategic partners, competition, changes in technology,
fluctuations  in   demand,  regulatory   requirements,   identifying,
developing and producing integrated products differentiated from  our
competitors'  products,  market  acceptance  of  our  products,   and
integration of  acquired  technologies and  businesses.  For  further
information, refer to our filings with the SEC, including our  latest
Form 20-F.  Information in  this release  is as  of the  date of  the
release, and we undertake no  duty to update this information  unless
required by law.


Public Relations                          Investor Relations
Dr. Thomas Theuringer                     Dr. Solveigh Maehler
Associate Director Public Relations       Director Investor Relations
+49 2103 29 11826                         +49 2103 29 11710

Nicole York                               Albert F. Fleury
Communications       Manager        North Investor Relations North
America                                   America
+ 1  240 686 7660                         +1 301 944 7028

email: [email protected]                      Email: [email protected]

This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.


a d v e r t i s e m e n t